Surgical resection is the preferred treatment for early-stage esophageal cancer. But most patients with esophageal cancer are diagnosed at advanced stages, making them ineligible for surgery. Therefore, preoperative neoadjuvant therapy has been introduced to help them meet surgical requirements. However, this therapy has been associated with serious complications, such as diarrhea, preventing patients from surgery. During neoadjuvant therapy combined with chemoradiotherapy, a 58-year-old male patient with esophageal cancer was diagnosed with severe immune-related colitis, which seriously affected both cancer treatment and the patient's quality of life. Despite conventional antidiarrheal therapy, the patient remained refractory to treatment. However, after undergoing fecal microbiota transplantation, the frequency of diarrhea was significantly reduced. During e-colonoscopy, no significant ulcers were found in the sigmoid colon. Additionally, successful radical resection of esophageal cancer was performed, resulting in a favorable outcome for the patient. Regular follow-up appointments were scheduled to monitor the patient's progress. Fecal microbiota transplantation effectively relieved severe immune-related diarrhea in a patient undergoing neoadjuvant immunotherapy and chemoradiotherapy for esophageal cancer. This successful treatment ultimately enabled the patient to meet the surgical requirements for radical esophagectomy.

中文翻译：

---

粪便微生物群移植可缓解食管癌新辅助治疗引起的严重 PD-1 抑制剂相关结肠炎：病例报告。


手术切除是早期食管癌的首选治疗方法。但大多数食管癌患者确诊时已属晚期，因此不适合接受手术。因此，引入术前新辅助治疗来帮助他们满足手术要求。然而，这种疗法与严重的并发症有关，例如腹泻，使患者无法进行手术。一名58岁男性食管癌患者在新辅助治疗联合放化疗期间，被诊断为重症免疫相关性结肠炎，严重影响了癌症治疗和患者的生活质量。尽管进行了常规止泻治疗，患者仍然难以治疗。然而，接受粪便微生物群移植后，腹泻的频率显着减少。电子结肠镜检查时，乙状结肠未发现明显溃疡。此外，成功进行了食管癌根治性切除术，为患者带来了良好的结果。安排定期随访预约以监测患者的进展。粪便微生物群移植有效缓解了接受食管癌新辅助免疫治疗和放化疗的患者的严重免疫相关性腹泻。这次成功的治疗最终使患者满足了食管癌根治术的手术要求。